125 related articles for article (PubMed ID: 8886299)
1. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers.
Koszycki D; Zacharko RM; Le Melledo JM; Young SN; Bradwejn J
Biol Psychiatry; 1996 Oct; 40(7):648-55. PubMed ID: 8886299
[TBL] [Abstract][Full Text] [Related]
2. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
Abelson JL; Nesse RM
Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
[TBL] [Abstract][Full Text] [Related]
3. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
McCann UD; Slate SO; Geraci M; Uhde TW
Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
[TBL] [Abstract][Full Text] [Related]
4. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
5. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.
Koszycki D; Zacharko RM; Le Mellédo JM; Bradwejn J
Depress Anxiety; 1998; 8(1):1-7. PubMed ID: 9750972
[TBL] [Abstract][Full Text] [Related]
6. Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.
Eser D; Leicht G; Baghai T; Pogarell O; Schüle C; Karch S; Nothdurfter C; Rupprecht R; Mulert C
J Psychiatr Res; 2009 Jan; 43(4):393-400. PubMed ID: 18534623
[TBL] [Abstract][Full Text] [Related]
7. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
Katzman MA; Duffin J; Shlik J; Bradwejn J
Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
[TBL] [Abstract][Full Text] [Related]
8. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
9. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
10. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
Demiralay C; Agorastos A; Yassouridis A; Jahn H; Wiedemann K; Kellner M
Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
[TBL] [Abstract][Full Text] [Related]
11. CCK-B receptor gene and response to cholecystokinin-tetrapeptide in healthy volunteers.
Koszycki D; Prichard Z; Fiocco AJ; Shlik J; Kennedy JL; Bradwejn J
Peptides; 2012 May; 35(1):9-13. PubMed ID: 22414867
[TBL] [Abstract][Full Text] [Related]
12. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
Shlik J; Vasar V; Aluoja A; Kingisepp PH; Jagomägi K; Vasar E; Rägo L; Bradwejn J
Biol Psychiatry; 1997 Aug; 42(3):206-12. PubMed ID: 9232213
[TBL] [Abstract][Full Text] [Related]
13. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
Ströhle A; Holsboer F; Rupprecht R
Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of cholecystokinin tetrapeptide on brain stem auditory evoked potentials in healthy volunteers.
Gunnarsson T; Mahoney C; Shlik J; Bradwejn J; Knott V
Pharmacopsychiatry; 2003 Sep; 36(5):181-6. PubMed ID: 14571352
[TBL] [Abstract][Full Text] [Related]
15. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep.
Kronenberg G; Schredl M; Fiedler K; Heuser I
Depress Anxiety; 2001; 14(2):141-4. PubMed ID: 11668667
[TBL] [Abstract][Full Text] [Related]
16. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
Tõru I; Shlik J; Maron E; Vasar V; Nutt DJ
Psychopharmacology (Berl); 2006 May; 186(1):107-12. PubMed ID: 16541242
[TBL] [Abstract][Full Text] [Related]
18. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F
Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
Fossa AA; DePasquale MJ; Morrone J; Zorn SH; Bryce D; Lowe JA; McLean S
J Pharmacol Exp Ther; 1997 Apr; 281(1):180-7. PubMed ID: 9103496
[TBL] [Abstract][Full Text] [Related]
20. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
Koszycki D; Torres S; Swain JE; Bradwejn J
Psychosom Med; 2005; 67(4):590-5. PubMed ID: 16046372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
